It is, however, known that patients with newly diagnosed hormone receptor (HR)-positive breast cancer (ER− and/or progesterone (PR)-positive disease) have a continuous long-term risk for fatal breast cancer progression relative to stage-matched patients with newly diagnosed HR-negative cancer [1]. Here, NR4A1 is linked to breast carcinoma.